Shots:

• The P-II (VERSATILE-002) trial evaluates PDS0101 + Merck’s Keytruda in 54 patients with advanced HPV-associated head & neck cancer. The trial is being studied in 2 groups i.e., patients who have not prior treated with CPI naïve in 1st group & failed prior therapy with CPI refractory in 2nd group of 21 patients
• The trial achieved the initial efficacy milestone & ORR as measured by radiographic tumor responses with tumor reduction of ~30% in 4+ of the 17 patients with CPI naïve arm & improve clinical outcomes
• The trial strengthens the ability of the Versamune platform to induce high levels of tumor-specific CD8+ killer T-cells that attack cancer to achieve tumor regression

Ref: Globe Newswire | Image: PDS